Sign up
Pharma Capital

Physiomics spies possible ‘nearer-term’ revenues from latest cancer tool

As part of an Innovate UK-funded project, Physiomics has developed a tool that could potentially help doctors work out how much of a chemotherapy drug should be prescribed to individual patients
iv drip in hospital
Physiomics received £68,000 from Innovate UK to cover the costs of the research

Physiomics Plc (LON:PYC) believes revenues from a tool it has developed as part of a project funded by Innovate UK could potentially be just around the corner.

Generally, doctors prescribe cancer patients with the same amount of a chemotherapy drug, but this can lead to under- or over-dosing individual patients, as each will respond differently.

As part of an Innovate UK-funded project, Physiomics has developed a tool that, from a simple blood test, could provide clinicians with a prediction of both toxicity and efficacy for any given dose.

READ: Renewal of key Merck contract caps off strong first half for Physiomics

They could then use this information to tailor the treatment to individual patients. This could potentially reduce the costs and morbidity associated with over-dosing, while it could also improve efficacy as a result of under-dosing.

Physiomics has said today it is exploring the approval of the tool as a medical device, although this would likely require further clinical validation before it could be commercialised.

But bosses pointed out that the tool could be used earlier in research settings, “thus creating the possibility of nearer term revenue potential”.

In support of the tool’s possible commercialisation, the AIM company is approaching potential strategic partners, clinical collaborators and grant providers to help it progress this “exciting opportunity”.

It has already presented a poster on the project at this year’s American Association for Cancer Research, which helped to drum up interest, while it has also spoken with the Oxford Academic Health Sciences Network and the National Institute for Health Research signposting service.

Physiomics cautioned that there is no guarantee this project will progress, although they will make an announcement later in the year should anything come of its discussions.

View full PYC profile View Profile
View All

Related Articles

Social media use
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.